Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIOP) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Fortress Biotech (FBIOP) over the last 13 years, with Q3 2025 value amounting to $86.2 million.

  • Fortress Biotech's Cash & Equivalents rose 4649.72% to $86.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.2 million, marking a year-over-year increase of 4649.72%. This contributed to the annual value of $57.3 million for FY2024, which is 2924.12% down from last year.
  • Latest data reveals that Fortress Biotech reported Cash & Equivalents of $86.2 million as of Q3 2025, which was up 4649.72% from $74.4 million recorded in Q2 2025.
  • Over the past 5 years, Fortress Biotech's Cash & Equivalents peaked at $305.7 million during Q4 2021, and registered a low of $57.3 million during Q4 2024.
  • Its 5-year average for Cash & Equivalents is $155.7 million, with a median of $91.3 million in 2025.
  • In the last 5 years, Fortress Biotech's Cash & Equivalents surged by 11324.89% in 2021 and then crashed by 6863.7% in 2023.
  • Quarter analysis of 5 years shows Fortress Biotech's Cash & Equivalents stood at $305.7 million in 2021, then plummeted by 41.69% to $178.3 million in 2022, then crashed by 54.6% to $80.9 million in 2023, then dropped by 29.24% to $57.3 million in 2024, then surged by 50.56% to $86.2 million in 2025.
  • Its Cash & Equivalents stands at $86.2 million for Q3 2025, versus $74.4 million for Q2 2025 and $91.3 million for Q1 2025.